Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia

Abstract

Several tyrosine kinase inhibitors (TKIs) are approved for chronic myeloid leukemia (CML) therapy. We evaluated the long-term cost-effectiveness of seven sequential therapy regimens for CML in Austria. A cost-effectiveness analysis was performed using a state-transition Markov model. As model parameters, we used published trial data, clinical, epidemiological and economic data from the Austrian CML registry and national databases. We performed a cohort simulation over a life-long time-horizon from a societal perspective. Nilotinib without second-line TKI yielded an incremental cost-utility ratio of 121 400 €/quality-adjusted life year (QALY) compared to imatinib without second-line TKI after imatinib failure. Imatinib followed by nilotinib after failure resulted in 131 100 €/QALY compared to nilotinib without second-line TKI. Nilotinib followed by dasatinib yielded 152 400 €/QALY compared to imatinib followed by nilotinib after failure. Remaining strategies were dominated. The sequential application of TKIs is standard-of-care, and thus, our analysis points toward imatinib followed by nilotinib as the most cost-effective strategy.

Keywords::

• Chronic myeloid leukemia
• decision-analytic model
• tyrosine kinase inhibitors
• decision analysis
• cost-effectiveness analysis
• health economic modeling

Acknowledgements

We thank Dr. Wolfgang Willenbacher for contributing his valuable expert knowledge on CML, Dr. Evelyn Walter for the assessment of economic parameters in Austria and Emily Burger for reviewing and editing the manuscript for the English language.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

Supplementary material available online

Supplementary Appendix